Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 95; no. 8; pp. 1435 - 1438
Main Authors ANTONIOLI, Elisabetta, CAROBBIO, Alessandra, RAMBALDI, Alessandro, BARBUI, Tiziano, VANNUCCHI, Alessandro M, PIERI, Lisa, PANCRAZZI, Alessandro, GUGLIELMELLI, Paola, DELAINI, Federica, PONZIANI, Vanessa, BARTALUCCI, Niccolò, TOZZI, Lorenzo, BOSI, Alberto
Format Journal Article
LanguageEnglish
Published Pavia Ferrata Storti Foundation 01.08.2010
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Alleles
Amino Acid Substitution
Biological and medical sciences
Diseases of red blood cells
Female
Gene Frequency
Hematologic and hematopoietic diseases
Humans
Hydroxyurea - therapeutic use
Janus Kinase 2 - genetics
Letter to the Editor
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Mutation
Nucleic Acid Synthesis Inhibitors - therapeutic use
Polycythemia Vera - drug therapy
Polycythemia Vera - enzymology
Polycythemia Vera - genetics
Polycythemias
Thrombocythemia, Essential - drug therapy
Thrombocythemia, Essential - enzymology
Thrombocythemia, Essential - genetics
Treatment Outcome
Young Adult
Antineoplastic agent
Human
Hydroxycarbamide
Hematology
Enzyme
JAK2 protein tyrosine kinase
Transferases
Polycythemia vera
Malignant hemopathy
Myeloproliferative syndrome
Essential thrombocythemia
Allele
hydroxyurea
Antimetabolic
Genetics
JAK2
Protein-tyrosine kinase
Cancer
Online AccessGet full text

Cover

More Information
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2009.021444